3. SAVOR-TIMI 53 Summary

4. SAVOR-TIMI 53: Primary End Point of CV Death, MI, Ischemic Stroke

5. SAVOR-TIMI 53 Microvascular End Points

6. SAVOR-TIMI 53 Safety Data Pancreatitis

7. EXAMINE

8. EXAMINE

9. Take-Home Message

11. Key Messages: SAVOR-TIMI 53 and EXAMINE

12. Reassurance Beyond CV Risk

13. SAVOR-TIMI 53 Possible Increase in HF

14. Integration of Data Into Cardiology Practice

16. Intersections of Diabetologists and Cardiologists

17. RECORD Trial: Rosiglitazone

18. CV Outcome Trials Evaluating DPP-4 Inhibitors Alogliptin and Saxagliptin

19. Takeaways

21. Guidelines Focus on Individualized Care

22. AHA World Health Organization Guidelines

23. Thoughts on SAVOR-TIMI 53 and EXAMINE From ESC

24. SAVOR-TIMI 53 and EXAMINE Takeaways

25. Perception and Data Interpretation

26. Guidelines Takeaway

28. Important Takeaways From Savor-TIMI 53 and EXAMINE

29. UKPDS: Patients With Potential for Improved CV Outcomes

30. Impacting Macrovascular Disease

31. Expanding Treatment Options

33. Results Are Neutral

34. No Harm Element From SAVOR-TIMI 53 and EXAMINE

35. Question Remaining:

36. Takeaway:

37. Summary: Overall Good News

38. Abbreviations

39. Abbreviations (cont)

40. References

41. References (cont)